Zhejiang U | College of Pharmaceutical Sciences | 中文版
     
     
Feng ZHU - IDRC - Chongqing University
ABOUT THE PRINCIPAL INVESTIGATOR

Dr. Feng ZHU

Tenured Full Professor, Doctoral Advisor, H-index & My Citations (Google Scholar)

Vice President of Youth Committee of CNPHARS Analytical Pharmacology and Chongqing Bioinformatics Society; Member of Analytical Pharmacology Committee of CNPHARS, Computational Chemistry Committee of CCS and Task Force on Bioinformatics Committee of CCF

zhufeng@zju.edu.cn (primary), prof.zhufeng@gmail.com; +86-571-88208444
PERSONAL DETAILS
Research Interests: Medicinal Chemistry, Drug Design, Target Discovery, Bioinformatics and System Biology

Based on the artificial intelligence and OMIC (proteomics and metabolomics) technologies, we conduct systematical exploration on the druggability and system profile of therapeutic drug targets, develop novel methods and online tools for target discovery, and further study the mechanism underlying the interaction between drugs and their corresponding targets.
  Academic Appointments and Educational Qualifications
  Honors and Awards
  • Leading Talent of the National High-Level Talent Special Support Plan of China (2020)

  • Honorable Professor of the Youth International Recruitment Program of China (2014)

  • Leading Talent of the Science & Technology Nova Program of Chinese MOST (2020)

  • Key Innovative Team Member of the Science & Technology Nova Program of Chinese MOST (2019)

  • Laureate of the Fund for Distinguished Young Scholars of Zhejiang Province (2021)

  • Honorable Professor of the High-level Talent Support Plan of Zhejiang Province (2018)

  • Supervisor of the Outstanding Doctor Postgraduate of Zhejiang Province (2021)

  • Supervisor of the Outstanding Master Postgraduate of Zhejiang Province (2020)

  • Laureate of the Leading Scholar in Social Practice of Jiusan Society (2021)

  • Laureate of the First Class Science & Technology Award of Chongqing Province (Ranked 4th, 2019)

  • Laureate of the First Class Shihuayu Teaching Scholarship of Zhejiang University (2021)

  • Supervisor of the Jiangzhi Biomedical Award of Zhejiang University (2020)

  • Supervisor of the Second Class Challenge Cup Award of Zhejiang University (2021)

  • Outstanding Professor of the 2019 Annual College/School Level Award of Zhejiang University, (2020)

  • Outstanding Professor of the 2018 Annual College/School Level Award of Zhejiang University, (2019)

  • Laureate of the Third Class Tanglixin Teaching Scholarship of Chongqing University (2014)

  • Laureate of the Top Cited Paper Award of Wiley Publication Group (2020)
  Research Grants (PI: Principal Investigator; PP: Project Participant)
    Project(s) on Going

  • 2021.02 - (PI): Fund for Future Digital Healthcare of Alibaba-ZJU Collaboration (ALIZJU202101)

  • 2021.01 - (PI): Fund for Distinguished Young Scholars of Zhejiang Province (LR21H300001)

  • 2021.01 - (PI): Postgraduate Education Reform Foundation of China (zyjyjx-grazju-49)

  • 2020.10 - (PI): National Leading Talent Special Support Plan of China (CWR-L-ZJU2020-ZF)

  • 2020.06 - (PI): Undergraduate Education Reform Foundation of China (068-484607)

  • 2020.01 - (PI): National Natural Science Foundation Collaboration Program of China (U1909208)

  • 2020.01 - (PI): Key Research and Development Program of Zhejiang Province (2020C03010)

  • 2019.01 - (PI): National Natural Science Foundation General Program of China (81872798)

  • 2018.09 - (PI): National Key Research and Development Program of China (2018YFC0910500)

  • 2018.01 - (PI): Youth Research Innovation Grant of Zhejiang University (2018QNA7023)

    • Project(s) Completed

  • 2017.07 - (PI): Hundreds Talents Program of Zhejiang University (ZJU2017070, evaluated as "Excellent")

  • 2016.08 - (PI): National Key Research and Development Program of China (2016YFC0902200)

  • 2015.12 - (PI): Special Fund for Chemical Drug Discovery of Chongqing Province (cstc2015zdcy-ztzx120003)

  • 2014.06 - (PI): Youth International Recruitment Program of China (IRPC-Y-CQU2014-ZF)

  • 2014.06 - (PI): Major Fund for Central Universities of Chongqing University (CDJZR14 46 88 01, evaluated as "Excellent")

  • 2013.01 - (PI): Key Fund for Central Universities of Chongqing University (CQDXWL-2012-Z003, evaluated as "Excellent")

  • 2013.01 - (PI): National Natural Science Foundation Youth Program of China (81202459)

  • 2012.09 - (PI): Natural Science Foundation General Program of Chongqing Province (cstc2012jjA10116)

  • 2012.07 - (PI): Hundreds Talents Program of Chongqing University (0903005203176, evaluated as "Excellent")
  Selected Publications (*corresponding author; highlighted graphic abstract; PDF version of paper)
  1. J. Y. Yin, F. C. Li, Y. Zhou, M. J. Mou, Y. J. Lu, K. L. Chen, J. Xue, Y. C. Luo, J. B. Fu, X. He, J. Q. Gao, S. Zeng*, L. S. Yu*, F. Zhu*. INTEDE: interactome of drug-metabolizing enzymes. Nucleic Acids Res (impact factor of the publication year: 11.501, 生物一区 TOP 期刊). 49(D1): 1233-1243 (2021).  
    2. Media Coverage & News Report:

  2. J. Tang, X. L. Wu, M. J. Mou, C. Wang, L. D. Wang, F. C. Li, M. Y. Guo, J. Y. Yin, W. Q. Xie, X. N. Wang, Y. X. Wang, Y. B. Ding*, W. W. Xue*, F. Zhu*. GIMICA: host genetic and immune factors shaping human microbiota. Nucleic Acids Res (impact factor of the publication year: 11.501, 生物一区 TOP 期刊). 49(D1): 715-722 (2021).  
    3. Media Coverage & News Report:

  3. Y. X. Wang, S. Zhang, F. C. Li, Y. Zhou, Y. Zhang, Z. W. Wang, R. Y. Zhang, J. Zhu, Y. X. Ren, Y. Tan, C. Qin, Y. H. Li, X. X. Li, Y. Z. Chen*, F. Zhu*. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res (impact factor of the publication year: 11.501, 生物一区 TOP 期刊). 48(D1): 1031-1041 (2020).  
    4. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.15% in 2021.
    Media Coverage & News Report:

  4. Q. X. Yang, Y. X. Wang, Y. Zhang, F. C. Li, W. Q. Xia, Y. Zhou, Y. Q. Qiu, H. L. Li, F. Zhu*. NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data. Nucleic Acids Res (impact factor of the publication year: 11.501, 生物一区 TOP 期刊). 48(W1): 436-448 (2020).  
    5. Media Coverage & News Report:

  5. J. Y. Yin, W. Sun, F. C. Li, J. J. Hong, X. X. Li, Y. Zhou, Y. J. Lu, M. Z. Liu, X. Zhang, N. Chen, X. P. Jin, J. Xue, S. Zeng*, L. S. Yu*, F. Zhu*. VARIDT 1.0: variability of drug transporter database. Nucleic Acids Res (impact factor of the publication year: 11.501, 生物一区 TOP 期刊). 48(D1): 1042-1050 (2020).  
    6. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.33% in 2021.
    Media Coverage & News Report:

  6. Y. H. Li, C. Y. Yu, X. X. Li, P. Zhang, J. Tang, Q. X. Yang, T. T. Fu, X. Y. Zhang, X. J. Cui, G. Tu, Y. Zhang, S. Li, F. Y. Yang, Q. Sun, C. Qin, X. Zeng, Z. Chen, Y. Z. Chen*, F. Zhu*. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res (impact factor of the publication year: 11.561, 生物一区 TOP 期刊). 46(D1): 1121-1127 (2018).  
    7.
    ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.15% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.14% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.16% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.36% in 2018.
    Highlights by Experts in Subject Area:
    • Introduced by OMICTOOLS as "useful for facilitating patient focused research, discovery and clinical investigations of the targeted therapeutics".

  7. B. Li, J. Tang, Q. X. Yang, S. Li, X. J. Cui, Y. H. Li, Y. Z. Chen, W. W. Xue, X. F. Li, F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Res (impact factor of the publication year: 10.162, 生物一区 TOP 期刊). 45(W1): 162-170 (2017).  
    8. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.72% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.75% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 1.27% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 2.98% in 2018.
    Highlights by Experts in Subject Area:
    • Introduced by OMICTOOLS as "provided valuable guidance to the selection of suitable algorithm in metabolomics".
    • Discussed in StackExchange as "works fine" and "corrections for batches without QC options".

  8. F. Zhu, Z. Shi, C. Qin, L. Tao, X. Liu, F. Xu, L. Zhang, Y. Song, X. H. Liu, J. X. Zhang, B. C. Han, P. Zhang, Y. Z. Chen*. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (impact factor of the publication year: 8.026, 生物一区 TOP 期刊). 40(D1): 1128-1136 (2012).  
    9. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.69% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.66% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.60% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.62% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 0.31% in 2017.

    Highlights by Experts in Subject Area:

    • "FACULTYof1000" as "the top 2% of published articles in biology and medicine" and "a most useful resource for scientists and companies working on drug discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations".
    • Prof. Chris Southan in his blog as "Therapeutic Target Database in PubChem".

  9. F. Zhu, B. C. Han, P. Kumar, X. H. Liu, X. H. Ma, X. N. Wei, L. Huang, Y. F. Guo, L. Y. Han, C. J. Zheng, Y. Z. Chen*. Update of TTD: therapeutic target database. Nucleic Acids Res (impact factor of the publication year: 7.479, 生物一区 TOP 期刊). 38(D1): 787-791 (2010).  
    10. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 2.95% in 2017.

  10. F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. H. Ma, J. Jia, Y. Tan, C. Cui, J. S. Lin, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A (impact factor of the publication year: 9.432, 综合性一区 TOP 期刊). 108(31): 12943-12948 (2011).  
    11. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.98% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.90% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.94% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 1.91% in 2017.
    Highlights by Experts in Subject Area: Media Coverage & News Report:

  11. J. J. Hong, Y. C. Luo, M. J. Mou, J. B. Fu, Y. Zhang, W. W. Xue, T. Xie, L. Tao*, Y. Lou*, F. Zhu*. Convolutional neural network-based annotation of bacterial type IV secretion system effectors with enhanced accuracy and reduced false discovery. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(5): 1825-1836 (2020).  

  12. Y. H. Li, X. X. Li, J. J. Hong, Y. X. Wang, J. B. Fu, H. Yang, C. Y. Yu, F. C. Li, J. Hu, W. W. Xue, Y. Y. Jiang, Y. Z. Chen*, F. Zhu*. Clinical trials, progression-speed differentiating features, and swiftness rule of the innovative targets of first-in-class drugs. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(2): 649-662 (2020).  
    13. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.08% in 2021.

  13. J. Tang, J. B. Fu, Y. X. Wang, B. Li, Y. H. Li, Q. X. Yang, X. J. Cui, J. J. Hong, X. F. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. ANPELA: analysis and performance-assessment of the label-free quantification workflow for metaproteomic studies. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(2): 621-636 (2020).  
    14. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.05% in 2021.

  14. Q. X. Yang, B. Li, J. Tang, X. J. Cui, Y. X. Wang, X. F. Li, J. Hu, Y. Z. Chen, W. W. Xue, Y. Lou, Y. Q. Qiu*, F. Zhu*. Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(3): 1058-1068 (2020).  
    15. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.19% in 2021.

  15. Z. J. Han, W. W. Xue, L. Tao, Y. Lou, Y. Q. Qiu*, F. Zhu*. Genome-wide identification and analysis of the eQTL lncRNAs in multiple sclerosis based on RNA-seq data. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(3): 1023-1037 (2020).  

  16. J. Tang, Y. X. Wang, J. B. Fu, Y. Zhou, Y. C. Luo, Y. Zhang, B. Li, Q. X. Yang, W. W. Xue, Y. Lou, Y. Q. Qiu*, F. Zhu*. A critical assessment of the feature selection methods used for biomarker discovery in current metaproteomic studies. Brief Bioinform (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(4): 1378-1390 (2020).  

  17. J. J. Hong, Y. C. Luo, Y. Zhang, J. B. Ying, W. W. Xue, T. Xie, L. Tao*, F. Zhu*. Protein functional annotation of simultaneously improved stability, accuracy and false discovery rate achieved by a sequence-based deep learning. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(4): 1437-1447 (2020).  

  18. Q. X. Yang, J. J. Hong, Y. Li, W. W. Xue, S. Li*, H. Yang*, F. Zhu*. A novel bioinformatics approach to identify the consistently well-performing normalization strategy for current metabolomic studies. Brief Bioinform (impact factor of the publication year: 9.101, 生物一区 TOP 期刊). 21(6): 2142-2152 (2020).  

  19. Y. X. Wang, F. C. Li, Y, Zhang, Y. Zhou, Y. Tan, Y. Z. Chen*, F. Zhu*. Databases for the targeted COVID-19 therapeutics. Br J Pharmacol (impact factor of the publication year: 7.730, 医学二区 TOP 期刊). 177: 4999-5001 (2020).  

  20. J. Tang, Y. X. Wang, Y. C. Luo, J. B. Fu, Y. Zhang, Y. Li, Z. Y. Xiao, Y. Lou, Y. Q. Qiu*, F. Zhu*. Computational advances of tumor marker selection and sample classification in cancer proteomics. Comput Struct Biotechnol J (impact factor of the publication year: 6.018, 生物二区 TOP 期刊). 18: 2012-2025 (2020).  

  21. J. Tang, J. B. Fu, Y. X. Wang, Y. C. Luo, Q. X. Yang, B. Li, G. Tu, J. J. Hong, X. J. Cui, Y. Z. Chen, L. X. Yao, W. W. Xue, F. Zhu*. Simultaneous improvement in the precision, accuracy and robustness of label-free proteome quantification by optimizing data manipulation chains. Mol Cell Proteomics (impact factor of the publication year: 5.236, 生物二区 TOP 期刊). 18(8): 1683-1699 (2019).  
    22. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.81% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.56% in 2020.

  22. F. C. Li, Y. Zhou, X. Y. Zhang, J. Tang, Q. X. Yang, Y. Zhang, Y. C. Luo, J. Hu*, W. W. Xue, Y. Q. Qiu, Q. J. He, B. Yang, F. Zhu*. SSizer: determining the sample sufficiency for comparative biological study. J Mol Biol (impact factor of the publication year: 5.067, 生物二区 TOP 期刊). 432(11): 3411-3421 (2020).  

  23. Y. Zhang, J. B. Ying, J. J. Hong, F. C. Li, T. T. Fu, F. Y. Yang, G. X. Zheng, X. J. Yao, Y. Lou, Y. Q. Qiu, W. W. Xue*, F. Zhu*. How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from Trichostatin A enantiomers based on molecular dynamics. ACS Chem Neurosci (impact factor of the publication year: 4.211, 化学二区 TOP 期刊). 10(5): 2467-2480 (2019).  
    24. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.19% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.90% in 2020.
    Cover Article:

  24. W. W. Xue, F. Y. Yang, P. P. Wang, G. X. Zheng, Y. Z. Chen, X. J. Yao, F. Zhu*. What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation. ACS Chem Neurosci (impact factor of the publication year: 4.211, 化学二区 TOP 期刊). 9(5): 1128-1140 (2018).  
    25. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 0.14% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.21% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.29% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 1.11% in 2018.

  25. P. P. Wang, X. Y. Zhang, T. T. Fu, S. Li, B. Li, W. W. Xue*, X. J. Yao, Y. Z. Chen, F. Zhu*. Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chem Neurosci (impact factor of the publication year: 4.348, 化学二区 TOP 期刊). 8(6): 1416-1428 (2017).  
    26. ESI Highly Cited Paper:
    • The Percentile in Subject Area shown in InCites™ was 1.48% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 1.80% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 1.32% in 2019.

  26. F. Y. Yang, G. X. Zheng, T. T. Fu, X. F. Li, G. Tu, Y. H. Li, X. J. Yao, W. W. Xue*, F. Zhu*. Prediction of binding mode and resistance profile for dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase associated ribonuclease H. Phys Chem Chem Phys (impact factor of the publication year: 4.123, 化学二区 TOP 期刊). 20(37): 23873-23884 (2018).  
    27. Back Cover Article:

  27. F. Zhu, L. Y. Han, C. J. Zheng, B. Xie, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical and system profile of successful targets. J Pharmacol Exp Ther (impact factor of the publication year: 3.867, 医学二区 TOP 期刊). 330(1): 304-315 (2009).  
    28. Successful Validation of the Constructed Model:
    • Pasireotide targeting Somatostatin receptor 1 was approved by FDA in 2011.
    • Fingolimod targeting S1P receptor was approved by FDA in 2010.
    • Ecallantide targeting Plasma Kallikrein was approved by FDA in 2009.
    • Cinryze targeting C1 esterase was approved by FDA in 2009.
    • Icatibant targeting BK-2 receptor was approved by FDA in 2008.
    • Plerixafor targeting CXCR4 was approved by FDA in 2008.

  28. Q. X. Yang, Y. X. Wang, F. C. Li, S. Zhang, Y. C. Luo, Y. Li, J. Tang, B. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. Identification of the gene signature reflecting schizophrenia's etiology by constructing artificial intelligence-based method of enhanced reproducibility. CNS Neurosci Ther (impact factor of the publication year: 3.394, 医学二区期刊). 25(9): 1054-1063 (2019).  
    29. Cover Article:

  29. Z. J. Han, W. W. Xue, L. Tao, F. Zhu*. Identification of novel immune-relevant drug target genes for alzheimer's disease by combining ontology inference with network analysis. CNS Neurosci Ther (impact factor of the publication year: 3.495, 医学二区期刊). 24(12): 1253-1263 (2018).  
    30. Honors and Awards:
    • Wiley Top Cited Paper Award (2020).
    Cover Article:

  Licensed Patents and Copyrights
  1. F. Zhu, M. J. Mou, J. Tang, Y. X. Wang, et al. Software Copyright 2021SR0027303 approved by the National NCAC of China.
    A Software Tool for Selecting Metaproteomic Features Based on Performance Assessment (2021)

  2. F. Zhu, J. Y. Yin, F. C. Li, X. X. Li, et al. Software Copyright 2021SR0822567 approved by the National NCAC of China.
    A Software Tool for Constructing Phylogenetic Tree Describing the Homology among Drug Transporters (2021)

  3. F. Zhu, F. C. Li, Y. Zhou, X. Y. Zhang. Software Copyright 2021SR0826823 approved by the National NCAC of China.
    A Software Tool for Determining Sample Sufficiency for Comparative Biological Study (2021)

  4. F. Zhu, S. Zeng, J. Y. Yin, F. C. Li. Software Copyright 2020SR0275172 approved by the National NCAC of China.
    A Software Tool for Analyzing the Interplay among the Variabilities of Drug Transporters (2020)

  5. F. Zhu, Y. X. Wang, Y. Z. Chen, S. Zhang, et al. Software Copyright 2020SR0526446 approved by the National NCAC of China.
    A Software Tool for Integrating the Epigenetics with the Protein-Protein Interactions of Drug Target (2020)

  6. F. Zhu, Y. X. Wang, S. Zhang, F. C. Li, et al. Software Copyright 2020SR0527384 approved by the National NCAC of China.
    A Software Tool for Strictly Validating the Primary Drug Target and Conducting Network Analysis (2020)

  7. F. Zhu, Y. X. Wang, S. Zhang, F. C. Li, et al. Software Copyright 2020SR0528155 approved by the National NCAC of China.
    A Software Tool for Strictly Identifying the Primary Therapeutic Target of the Drugs in Clinical Trial (2020)

  8. F. Zhu, J. J. Hong, J. Hu, L. Tao. Software Copyright 2020SR0274064 approved by the National NCAC of China.
    A Software Tool for Discovering the Bacterial Type-IV Secreting System Effector Protein (2019)

  9. F. Zhu, J. Tang, J. B. Fu, Y. X. Wang. Software Copyright 2020SR0274135 approved by the National NCAC of China.
    A Software Tool for Assessing Label-free Proteome Quantification from Multiple Perspectives (2019)

  10. F. Zhu, F. C. Li, S. Zhang, Y. X. Wang, et al. Software Copyright 2020SR0525443 approved by the National NCAC of China.
    A Software Tool for Discovering the Novel Drug Scaffold Based on Biomarker Identification (2019)

  11. F. Zhu, F. C. Li, S. Zhang, Y. X. Wang, et al. Software Copyright 2020SR0528147 approved by the National NCAC of China.
    A Software Tool for Identifying the Tissue-Specific Distribution Pattern of Therapeutic Target (2018)

  12. F. Zhu, Q. X. Yang, B. Li, Y. X. Wang. Software Copyright 2020SR0275177 approved by the National NCAC of China.
    A Software Tool for Evaluating Mass-spectrometry-based Metabolomic Data from Multiple Perspectives (2017)

  13. F. Zhu, S. Zhang, F. C. Li, Y. X. Wang, et al. Software Copyright 2020SR0528618 approved by the National NCAC of China.
    A Software Tool for Associating the Disease-Relevant Signaling Pathway with Therapeutic Target (2016)
  Hosted Conference and Symposium
  Invited Speaker of International/Domestic Conference
  Reviewer of Esteemed Journals (12 Representative Journals)
Nucleic Acids Res (IF = 11.501); Med Res Rev (IF = 9.300); Br J Pharmacol (IF = 7.730);
Nat Protoc (IF = 10.419); Brief Bioinform (IF = 8.990); Bioinformatics (IF = 5.610);
Proc Natl Acad Sci U S A (IF = 9.412); Anal Chem (IF = 6.785); Mol Pharmaceut (IF = 4.321);
J Med Chem (IF = 6.205); Pharmacol Res (IF = 5.893); J Chem Inf Model (IF = 4.549)
  Associate Editor/Editorial Board Member/Topic Editor of Journals
Front Pharmacol (IF = 4.225); Comput Biol Med (IF = 3.434); J Alzheimers Dis (IF = 3.909);
Curr Gene Ther (IF = 2.431); Protein Pept Lett (IF = 1.156); Prog Pharm Sci (IF = N.A.)
IDRB: Innovative Drug Research and Bioinformatics Group


All rights are reserved by: Innovative Drug Research and Bioinformatics Group (IDRB)
College of Pharmaceutical Sciences, Zhejiang University
Hangzhou, P.R. China, 310058.
Contact number: (86 - 571)88208444
ICP ID: 浙ICP备18036997号-1

Last Update: